173 related articles for article (PubMed ID: 35286688)
41. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
42. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Salhotra A; Yang D; Mokhtari S; Malki MMA; Ali H; Sandhu KS; Aribi A; Khaled S; Mei M; Budde E; Snyder D; Cao T; Spielberger R; Marcucci G; Pullarkat V; Forman SJ; Nakamura R; Stein A; Aldoss I
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1084-1090. PubMed ID: 32035275
[TBL] [Abstract][Full Text] [Related]
43. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
[TBL] [Abstract][Full Text] [Related]
44. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
Yasuda S; Najima Y; Konishi T; Yamada Y; Nagata A; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Shingai N; Yoshioka K; Inamoto K; Mukae J; Toya T; Igarashi A; Shimizu H; Kobayashi T; Kakihana K; Sakamaki H; Kawamata N; Ohashi K; Doki N
Leuk Res; 2021 Sep; 108():106627. PubMed ID: 34062327
[TBL] [Abstract][Full Text] [Related]
45. [State-of-the-art therapy for adult Philadelphia chromosome-negative acute lymphoblastic leukemia].
Hatta Y
Rinsho Ketsueki; 2020; 61(9):1236-1243. PubMed ID: 33162521
[TBL] [Abstract][Full Text] [Related]
46. Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
Zeng Q; Xiang B; Liu Z
Cancer Med; 2021 Dec; 10(24):8741-8753. PubMed ID: 34761879
[TBL] [Abstract][Full Text] [Related]
47. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
[TBL] [Abstract][Full Text] [Related]
48. CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy.
Isshiki Y; Ohwada C; Sakaida E; Onoda M; Aotsuka N; Tanaka H; Fukazawa M; Cho R; Sugawara T; Kawaguchi T; Hara S; Yokota A
Jpn J Clin Oncol; 2017 Nov; 47(11):1047-1054. PubMed ID: 28973362
[TBL] [Abstract][Full Text] [Related]
49. Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease.
Chen J; Ngo D; Rosenthal J
J Oncol Pharm Pract; 2019 Dec; 25(8):2027-2030. PubMed ID: 30537919
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of blinatumomab: a real world data.
Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
[TBL] [Abstract][Full Text] [Related]
51. Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantation.
Hu M; Wang H; Wang L; Yang M; Lou Y; Jin J
Medicine (Baltimore); 2018 Jul; 97(28):e11374. PubMed ID: 29995776
[TBL] [Abstract][Full Text] [Related]
52. Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data.
Barlev A; Lin VW; Katz A; Hu K; Cong Z; Barber B
Adv Ther; 2017 Jan; 34(1):148-155. PubMed ID: 27873237
[TBL] [Abstract][Full Text] [Related]
53. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Queudeville M; Schlegel P; Heinz AT; Lenz T; Döring M; Holzer U; Hartmann U; Kreyenberg H; von Stackelberg A; Schrappe M; Zugmaier G; Feuchtinger T; Lang P; Handgretinger R; Ebinger M
Eur J Haematol; 2021 Apr; 106(4):473-483. PubMed ID: 33320384
[TBL] [Abstract][Full Text] [Related]
54. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
55. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
[TBL] [Abstract][Full Text] [Related]
56. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
[TBL] [Abstract][Full Text] [Related]
57. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Topp MS; Fielding AK; Rambaldi A; Ritchie EK; Papayannidis C; Sterling LR; Benjamin J; Stein A
J Clin Oncol; 2017 Jun; 35(16):1795-1802. PubMed ID: 28355115
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Kobayashi Y; Oh I; Miyamoto T; Lee WS; Iida H; Minami H; Maeda Y; Jang JH; Yoon SS; Yeh SP; Tran Q; Morris J; Franklin J; Kiyoi H
Asia Pac J Clin Oncol; 2022 Jun; 18(3):311-318. PubMed ID: 34185953
[TBL] [Abstract][Full Text] [Related]
59. Blinatumomab (Blincyto) for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 2015 May; 57(1468):e74-5. PubMed ID: 25941958
[TBL] [Abstract][Full Text] [Related]
60. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Couturier MA; Thomas X; Raffoux E; Huguet F; Berthon C; Simand C; Gallego-Hernanz MP; Hicheri Y; Hunault Berger M; Saillard C; Leguay T; Loiseau C; Béné MC; Chevallier P
Leuk Lymphoma; 2021 Mar; 62(3):620-629. PubMed ID: 33153370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
